Study on Pembrolizumab with Chemoradiation Therapy, Followed by Pembrolizumab with or without Olaparib, for Stage III Non-Small Cell Lung Cancer

Inclusion Criteria

• Diagnosed with non-small cell lung cancer (NSCLC) confirmed by lab tests.
• Have Stage IIIA, IIIB, or IIIC NSCLC, meaning the cancer is locally advanced but not spread to distant parts of the body.
• Cannot have surgery to remove the cancer.
• No evidence of cancer spread to distant organs (Stage IV).
• Have measurable cancer that can be tracked using standard criteria.
• Have not received prior treatment for Stage III NSCLC, except for early-stage treatments.
• Provide a tumor tissue sample for analysis.
• Be in good overall health with a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have a life expectancy of at least 6 months.
• Men must agree to use contraception and not donate sperm during and after treatment for a specified time.
• Women must not be pregnant or breastfeeding and agree to use contraception and not donate eggs during and after treatment for a specified time.
• Have a negative pregnancy test before starting treatment.
• Have adequate lung and organ function.
• Provide written informed consent to participate.

Exclusion Criteria

• Have small cell lung cancer or a mixed tumor with small cell elements.
• Have certain blood disorders like myelodysplastic syndrome or acute myeloid leukemia.
• Have lost more than 10% of body weight in the last 3 months.
• Have had prior radiation to the chest area.
• Have received certain immune therapies or olaparib before.
• Have had major surgery recently, except for minor procedures.
• Need other cancer treatments during the study.
• Have received a live vaccine recently.
• Are taking certain medications that affect the liver or immune system.
• Cannot stop taking aspirin or other medications as required by the study.
• Have received an investigational drug or device recently.
• Have uncontrolled heart conditions or long QT syndrome.
• Have a weakened immune system or are on immunosuppressive therapy.
• Have another active cancer needing treatment, except for certain skin or bladder cancers.
• Have severe allergies to study drugs.
• Have an active autoimmune disease needing treatment.
• Have a history of lung inflammation needing steroids.
• Have an active infection needing treatment.
• Have a history of HIV, Hepatitis B, or active Hepatitis C.
• Have active tuberculosis.
• Have any condition that might interfere with the study or make participation unsafe.
• Have a psychiatric or substance abuse disorder affecting study participation.
• Cannot swallow pills or have a digestive disorder affecting absorption.
• Have had a tissue or organ transplant.